Close
Michael Liss, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Michael Liss, M.D.
Dr. Michael Liss specializes in cancer of the genitourinary system including kidney cancer and prostate cancer. After graduating with honors in research from the Medical School of Wisconsin, he attended the University of California, Irvine and trained under leaders in laparoscopic and robotic urology. He completed a two-year fellowship in urologic oncology at the University of California, San Diego. The fellowship is approved by the Society of Urologic Oncology. During this intensive training, he completed a Masters of Applied Science in Clinical Trials (MAS).
Currently, Dr. Liss is the site principal investigator for SWOG, formerly the Southwest Oncology Group, one of the largest cooperative clinical trial groups in the world. He also serves as the medical director of clinical research at University Hospital. Dr. Liss is also an active member of the cancer center's genetics and high risk cancer screening clinic focusing on patients at high risk for kidney cancer and prostate cancer.
Gender
- Male
-
Credentials
Credentials
Certifications
- American Board of Urology
Education
- Medical School: University of California at San Diego
- Internship: University of California, Irvine
- Residency: University of California - Irvine Medical Center
- Fellowship: University of California at San Diego
-
Locations & Contact
Locations & Contact
Dr. Liss is one of the best doctors that has treated me at the University, Thank you.
Patient
-
Research & Publications
Research & Publications
No Research & Publications
-
Clinical Trials
Clinical Trials
Type of Cancer
Prostate
ClinicalTrials.gov Identifier
NCT01436968
Principal Investigator
Michael Liss M.D.
A RANDOMIZED CONTROLLED TRIAL OF PROSTATAK® AS ADJUVANT TO UP-FRONT RADIATION THERAPY FOR LOCALIZED PROSTATE CANCER
This randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation before surgery in treating patients with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as fluorouracil, irinotecan…
Type of Cancer
Prostate
ClinicalTrials.gov Identifier
NCT03697148
Principal Investigator
Michael Liss M.D.
EA8171, Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer (CTMS# 18-0091)
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Michael Liss M.D.
EA8191: Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE). (CTMS# 21-0109)
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Michael Liss M.D.
Validation, Calibration, and Translation of Restriction Spectrum Imaging Signal Maps to enhance MRI diagnostic capabilities in Prostate Cancer (CTMS# 22-0158)